Premium
Combination Plant Sterol/Ezetimbe Therapy in Modulation of Plasma Lipids in Syrian Golden Hamsters
Author(s) -
Rideout Todd C,
Ramprasath Vanu Ramkumar,
Senanayake Vijitha,
Jones Peter JH
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.594.1
Plant sterols (PS) and ezetimibe (EZ) are well‐characterized diet and drug lipid‐lowering therapies, respectively, that work through distinct mechanisms to reduce intestinal cholesterol absorption. Combination PS/EZ therapy may be effective in reducing blood cholesterol (C) concentrations in patients who respond suboptimally to either therapy alone. The objective of this study was to conduct a pre‐clinical assessment of the efficacy of a PS/EZ combination in protecting against diet‐induced dyslipidemia. Eighty‐four Syrian Golden hamsters (n=12) were randomly assigned to one of the following diets for 6 weeks: low fat diet (LFD); atherogenic diet (AD); AD supplemented with 2% PS (PSD); AD supplemented with 0.002% ezetimibe (EZD); or the AD supplemented with PS and EZ (PS/EZ). Consumption of the AD increased (P<0.05) plasma total‐C (8.1%), HDL‐C (9.2%), non‐HDL‐C (6.7%), and triglycerides (17.9%) compared with the LFD. Compared with the AD, both PS and EZ monotherapy reduced endpoint plasma total‐C (10.3 vs 12.3%), non‐HDL‐C (22.1 vs 25.1%), and triglycerides (14.4 vs 22.5%). Lipid reductions in response to PS/EZ were similar (P>0.05) to both the PS and EZ treatments alone. Although both PS and EZ monotherapy were effective in protecting against diet‐induced dyslipidemia, combination PS/EZ therapy did not provide additional lipid‐lowering benefit. Supported by NSERC.